¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"control gene"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • infection control surveillance
    °¨¿°°ü¸®°¨½Ã
  • injury control
    »óÇØ°ü¸®
  • insect control
    °ïÃæ±¸Á¦
  • laboratory infection control
    °Ë»ç½Ç°¨¿°°ü¸®
  • leprosy control program
    ³ªº´°ü¸®»ç¾÷
  • local control
    ±¹¼ÒÁ¦¾î
  • matched control
    ¦ÁöÀº´ëÁ¶±º
  • membrane control protein
    ¸·Á¶Àý´Ü¹éÁú
  • neighborhood control
    ÀÌ¿ô´ëÁ¶±º
  • nosocomial infection control
    º´¿ø³»°¨¿°°ü¸®
  • pain control
    ÅëÁõÁ¶Àý
  • quality control
    Áú°ü¸®, Á¤µµ°ü¸®, ǰÁú°ü¸®
  • quality control program
    Áú°ü¸®ÇÁ·Î±×·¥
  • reflex control
    ¹Ý»çÁ¶Àý
  • regional quality control program
    Áö¿ªÁú°ü¸®ÇÁ·Î±×·¥
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • gonosomal gene
    ¼º¿°»öüÀ¯ÀüÀÚ
  • histocompatibility gene
    Á¶Á÷ÀûÇÕÇ׿øÀ¯ÀüÀÚ
  • hox gene
    Ȥ½ºÀ¯ÀüÀÚ
  • human leukocyte antigen complex gene
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕüÀ¯ÀüÀÚ
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ
  • lethal gene
    Ä¡»çÀ¯ÀüÀÚ
  • major histocompatibility gene
    ÁÖÁ¶Á÷ÀûÇÕ¼ºÀ¯ÀüÀÚ
  • marker gene
    Ç¥ÁöÀ¯ÀüÀÚ
  • modulator gene
    ÀÛµ¿À¯ÀüÀÚ, ¸Å°³À¯ÀüÀÚ
  • molecular check point gene
    ºÐÀڰ˹®À¯ÀüÀÚ
  • mutant gene
    µ¹¿¬º¯ÀÌÀ¯ÀüÀÚ
  • mutator gene
    º¯ÀÌÀ¯¹ßÀ¯ÀüÀÚ
  • nucleolar gene
    ÇÙ¼ÒüÀ¯ÀüÀÚ
  • operator gene
    ÀÛµ¿À¯ÀüÀÚ
  • recessive gene
    ¿­¼ºÀ¯ÀüÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • DR gene
    DRÀ¯ÀüÀÚ
  • Gag gene
    gag À¯Àü(ÀÎ)ÀÚ
  • Gene therapy
    À¯ÀüÀÚÄ¡·á(ö½Öû)
  • Hfr mediated gene transfer
    °íºóµµÀçÁ¶ÇÕ¼¼Æ÷¸Å°³ À¯ÀüÀÚÀüÀÌ
  • Onc gene
    Onc À¯ÀüÀÚ
  • Src gene
    Src À¯Àü(ÀÎ)ÀÚ
  • T cell receptor gene
    T¼¼Æ÷[Ç׿ø]¼ö¿ëü À¯ÀüÀÚ
  • additive gene
    »ó°¡À¯ÀüÀÚ(ßÓÊ¥ë¶îîí­).
  • aniridia,pax-6 gene
    PAX-6 À¯ÀüÀÚ(¡­ë¶îîí­)
  • apc gene
    APC À¯ÀüÀÚ(¡­ë¶îîí­)
  • gene
    À¯ÀüÀÚ(ë¶îîí­)
  • gene
    À¯ÀüÀÚ
  • gene amplification
    À¯ÀüÀÚÁõÆø
  • gene amplification
    À¯ÀüÀÚ ÁõÆø
  • gene analyses
    À¯ÀüÀںм®
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • control level
    °ü¸®¼öÁØ(Ë´ËöËàÌ¡).
  • control limit
    °ü¸®ÇѰè(Ë´Ëö̰˭).
  • control mechanism
    Á¶Àý±âÀü
  • control mode ventilation
    Á¶Àýȯ±â¹ý
  • control of bleeding
    ÁöÇ÷¹ý(ò­úìÛö).
  • control of bleeding
    ÁöÇ÷(ÁöÇ÷).
  • control of epidemics
    À¯Çິ°ü¸®(ËôÌ´ËÓ Ë´Ëö).
  • control of light
    Á¶¸íÁ¶Àý(Ì¡ËÎÌ¡Ëø).
  • control of ventilation
    ȯ±âÁ¶Àý(Ì·Ë»Ì¡Ëø).
  • control of ventilation
    ȯ±âÁ¶Àý(üµÑ¨ðàï½).
  • control test
    ´ëÁ¶½ÃÇè(ÊÙËàÌ´).
  • control tube
    Á¦¾î°ü(¡­Î·), Á¶Á¤(ðàïÚ)Æ©¿ìºê.
  • control tube
    Á¦¾î°ü(ÊÙË´), Á¶Á¤(Ì¡Ëø)Æ©¿ìºê.
  • control valve
    Á¶Àý¹ëºê, Á¶ÀýÆÇ(¡­÷û).
  • control, relaxed
    ÇØÀ̺¹Á¦Á¶Àý
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • early gene
    Á¶±â À¯ÀüÀÚ (ðÄÑ¢ë¶îîí­)
  • epistatic gene
    ¿ìÀ§ À¯ÀüÀÚ (éÐêÈë¶îîí­)
  • essential gene
    Çʼö À¯ÀüÀÚ (ù±âÎë¶îîí­)
  • fused gene
    À¶ÇÕ À¯ÀüÀÚ(ë×ùêë¶îîí­)
  • fusion gene
    À¶ÇÕ À¯ÀüÀÚ(ë×ùêë¶îîí­)
  • gene
    À¯ÀüÀÚ(ë¶îîí­)
  • gene activation
    À¯ÀüÀÚ È°¼ºÈ­(ë¶îîí­üÀàõûù)
  • gene amplification
    À¯ÀüÀÚ ÁõÆø(ë¶îîí­ñòøë)
  • gene bank
    À¯ÀüÀÚ ÀºÇà(ë¶îîí­ëÞú¼)
  • gene cloning
    À¯ÀüÀÚ(ë¶îîí­) Ŭ·Î´×
  • gene cluster
    À¯ÀüÀÚ(ë¶îîí­) ¼ÛÀÌ
  • gene conversion
    À¯ÀüÀÚ Àüȯ(ë¶îîí­ï®üµ)
  • gene dosage
    À¯ÀüÀÚ ·®(ë¶îîí­Õá)
  • gene duplication
    À¯ÀüÀÚ º¹»ç(ë¶îîí­ÜÜÞÐ)
  • gene expression
    À¯ÀüÀÚ ¹ßÇö(ë¶îîí­Û¡úÞ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
cGRP calcitonin gene-related peptide
CGRPR calcitonin gene related peptide receptor
che a gene involved in chemotaxis
CMGT chromosome-mediated gene transfer
CRYG gamma crystallin gene
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CDC Center for Disease Control
CDC Centre for Disease Control
CCP Complement Control Protein
control Concentrations of 0
control Contralateral
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • control valve
    Á¶Àý ¹ëºê, Á¶ÀýÆÇ
  • laser hazard control measure
    ·¹ÀÌÀú À§ÇØÁ¶Àý¹ý
    ·¹ÀÌÀú°¡ Áö´Ñ ¾öû³­ ¿¡³ÊÁö´Â ÀÎü¿¡ ÇØ°¡ µÉ ¼ö ÀÖÀ¸¹Ç·Î µÇµµ·Ï ·¹ÀÌÀú¸¦ »ç¿ëÇÏ´Â »ç¶÷µéÀÌ ¼Õ»óÀ» ¹ÞÁö ¾Êµµ·Ï ÇÏ´Â ¹æ¹ý.
  • leprosy control
    ³ª °ü¸®
    °³³ä»ó, ÁÖ¹ÎÀ» ³ª±ÕÀÇ Àü¿°À¸·ÎºÎÅÍ º¸È£ÇÏ´Â ¿¹¹æ °ü¸®¿Í, ³ªÈ¯ÀÚ¸¦ ³ª±ÕÀ¸·ÎºÎÅÍ ¿À´Â À°Ã¼Àû, Á¤½ÅÀû °íÅëÀ» ´ú¾î ÁÖ´Â Áø·á °ü¸®ÀÇ µÎ °¡Áö·Î ºÐ·ùÇÒ ¼ö ÀÖ´Ù. ¨ç ¿¹¹æ °ü¸®´Â Àü¿°¿øÀ» Â÷´ÜÇÏ´Â °ÍÀ» ¸»Çϴµ¥, ³ª ȯÀÚ¸¦ °Ý¸®ÇÔÀ¸·Î½á ³ªº´ÀÇ Àü¿°¿øÀÌ Â÷´ÜµÈ´Ù°í »ý°¢Çß´ø ½Ã´ë¿¡´Â ³ª ȯÀÚ Àü¿øÀ» °Ý¸® ¼ö¿ëÇÏ¿´´Ù. ±×·¯³ª Àüü ³ª ȯÀÚ Áß ±ØÈ÷ ÀϺÎÀÇ ¹Ì°ü¸®ÇÏ¿¡ Àִ ȯÀÚ¸¸ÀÌ Àü¿°¿øÀÌ µÈ´Ù´Â »ç½ÇÀÌ ¹àÇôÁø ¿À´Ã³¯¿¡´Â, ³ª ȯÀÚ·Î È®ÀÎÀÌ µÇ¾î ¾àÁ¦ Åõ¿©°¡ ½ÃÀÛµÈ ÈÄ¿¡´Â Àü¿°¿øÀÌ µÉ ¼ö ¾ø´Ù´Â °á·Ð¿¡ À̸£·¶´Ù. ÀÌ¿¡ µû¶ó ¿À´Ã³¯¿¡´Â ÀÏ¹Ý ÇǺΠÁúȯÀÚ¿Í °°ÀÌ ÀÚÀ¯·ÎÀÌ »ý¾÷¿¡ Á¾»çÇϸç Áø·á¸¦ ¹Þ°í ÀÖ´Ù. ¨è Áø·á °ü¸®´Â Àǻ簡 Á¤È®ÇÑ Áø´Ü°ú º´Çü ºÐ·ù¸¦ ¹ÙÅÁÀ¸·Î ÀûÇÕÇÑ Ã³¹æÀ» ³»¸®°í ȯÀÚ°¡ ¼º½ÇÇÏ°Ô ¾àÀ» º¹¿ëÇÏ´Â °ÍÀÌ´Ù. ¹®Á¦´Â ³ªº´ÀÌ ¸¸¼ºÀûÀ¸·Î °æ°úÇÏ´Â Àå±â ÁúȯÀε¥´Ù Ä¡·áÀÇ ¼º°ú°¡ Áï½Ã ³ªÅ¸³ªÁö ¾ÊÀ¸¹Ç·Î 󹿰ú º¹¾àÀÌ ³ªÅÂÇØÁ® Ä¡·á°¡ ºÒ±ÔÄ¢ÇØÁö°í ¾àÁ¦ ³»¼ºÀ» ¹ßÀü½ÃŰ´Â µ¥ µû¸¥ °ü¸®»óÀÇ ¾î·Á¿òÀÌ ÀÖ´Ù. ³ªº´¿¡ ´ëÇÑ Æí°ßÀ» ¾ø¾Ö°í ±¹¹ÎÀû ÀÌÇØ¿Í Âü¿©¿¡ ÀÇÇØ Á¶±â ¹ß°ß ¹× Ä¡·á¿¡ ÀÓÇÑ´Ù¸é ³ªº´ °ü¸®¸¦ À§ÇÑ Æ¯¼ö ½Ã¼³À̳ª ±â°üÀÌ ÇÊ¿ä¾ø°Ô µÉ °ÍÀÌ´Ù.
  • nociceptive control
    Ä§ÇØ ¼ö¿ë¼º Á¶Àý, À¯ÇØ ¼ö¿ë¼º Á¶Àý
  • pest control
    À¯ÇØ »ý¹° Á¦¾î
  • plaque control
    ġŠÁ¶Àý
  • proper direction and control
    ÀûÀýÇÑ Áöµµ¿Í ÅëÁ¦
  • pulse control unit
    ¸Æ¹Ú Á¶Àý ´ÜÀ§
  • quality control program
    Á¤µµ °ü¸® °èȹ
  • reasonable emotional control
    ÇÕ¸®Àû Á¤¼­ Á¶Àý
  • regular control
    ±ÔÄ¢ÀûÀÎ Á¶Àý
  • self-control
    ÀÚ°¡ Á¶Àý¹ý
    °³ÀÎÀÇ ½Å³ä ¸ñÇ¥ ¹× ŵµ¿¡ µû¶ó¼­ ÀÚ±âÀÇ ÇൿÀ» ½º½º·Î Á¶ÀýÇÏ´Â °Í.
  • stringent control
    ¾ö°Ý Á¶Àý
  • sulfur dioxide control
    ÀÌ»êÈ­ Ȳ °¡½º ±ÔÁ¦
  • time gain control
    ½Ã°£ °ÔÀÎ Á¶Àý
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
control group A group of subjects participating in the same experiment as another group of subjects, but which is not exposed to the variable under investigation.
See: experimental group.
(05 Mar 2000)
control limit A regulatory value applied to the airborne concentration in the workplace of a potentially poisonous substance which is judged to be reasonably practicable for the whole spectrum of work activities and which must not normally be exceeded.
(09 Oct 1997)
Control of Communicable Diseases in Man The internationally recognised authoritative manual now in the 15th (1990) edition, published by the American Public Health Association.
(05 Mar 2000)
control plot A plot in which no vegetation will be cut and natural succession will occur. A control plot serves as a baseline to compare other treatments (Early, Mid and Late Seral).
(05 Dec 1998)
control release suture Eyeless suture with thread attached to needle such that the two separate when tension is applied to the thread.
(05 Mar 2000)
control syringe A type of Luer-Lok syringe with thumb and finger rings attached to the proximal end of the barrel and to the tip of the plunger, allowing operation of the syringe with one hand.
Synonym: ring syringe.
(05 Mar 2000)
poison control centres Facilities which provide information concerning poisons and treatment of poisoning in emergencies.
(12 Dec 1998)
cost control The containment, regulation, or restraint of costs. Costs are said to be contained when the value of resources committed to an activity is not considered excessive. This determination is frequently subjective and dependent upon the specific geographic area of the activity being measured.
(12 Dec 1998)
population control Includes mechanisms or programs which control the numbers of individuals in a population of humans or animals.
(12 Dec 1998)
positive control Mechanism for gene regulation that requires that a regulatory protein must interact with some region of the gene before transcription can be activated.
(18 Nov 1997)
self-control 1. Self-regulation of one's behaviour in accordance with personal beliefs, goals, attitudes and societal expectations.
2. Use by an individual of active coping strategies to deal with problem situations, in contrast to passive conditioning strategies which do things to the individual and require no action by the person.
(05 Mar 2000)
social control The influence on the behaviour of a person exerted by other persons or by society as a whole; e.g., through appropriate social norms, ostracism, or the criminal law.
(05 Mar 2000)
social control, formal Control which is exerted by the more stable organizations of society, such as established institutions and the law. They are ordinarily embodied in definite codes, usually written.
(12 Dec 1998)
social control, informal Those forms of control which are exerted in less concrete and tangible ways, as through folkways, mores, conventions, and public sentiment.
(12 Dec 1998)
social control policies Decisions for determining and guiding present and future objectives from among alternatives.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • control clock
    ±âÁØ ½Ã°è(master clock)
  • control column
    Á¶Á¾·û(Â÷ÀÇ ÇÚµé½Ä Á¶Á¤°£)
  • control experiment
    ´ëÁ¶ ½ÇÇè
  • control grid
    (ÀüÀÚ°üÀÇ)Á¦¾î ±×¸®µå(°ÝÀÚ)
  • control group
    Á¦¾îÁý´Ü;Á¶Á¾ÀåÄ¡;´ëÁ¶±º(µ¿ÀϽÇÇè¿¡¼­ ½ÇÇè¿ä°ÇÀ» °¡ÇÏÁö ¾ÊÀº ±×·ì)
  • control lever
    =CONTROL STICK
  • control panel
    =CONTROL BOARD
  • control rod
    (¿øÀÚ·ÎÀÇ)Á¦¾îºÀ
  • control room
    °üÁ¦½Ç;(¿øÀڷ½ü³µîÀÇ)Á¦¾î½Ç;(¹æ¼Û±¹µîÀÇ)Á¶Á¤½Ç
  • control stick
    Á¶Á¾°£
  • control storage
    Á¦¾î±â¾ïÀåÄ¡
  • control tower
    (°øÇ×ÀÇ)°üÁ¦Å¾
  • damage control
    ÀÀ±Þ ÇÇÇØ ´ëÃ¥;ÇÇÇØ ´ëÃ¥¹Ý
  • dual control
    ÀÌÁß °üÇÒ;¾ç±¹ °øµ¿ ÅëÄ¡;(°ø)ÀÌÁß Á¶Á¾ ÀåÄ¡
  • exchange control
    ȯ°ü¸®
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á